relacatib   Click here for help

GtoPdb Ligand ID: 7862

Synonyms: SB-462795 | SB462795
Compound class: Synthetic organic
Comment: Relacatib is a cathepsin K inhibitor, developed by GlaxoSmithKline and selected for clinical development in osteoporosis.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 147.06
Molecular weight 540.2
XLogP 3.17
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(CC(C(=O)NC1CCC(N(CC1=O)S(=O)(=O)c1ccccn1)C)NC(=O)c1cc2c(o1)cccc2)C
Isomeric SMILES CC(C[C@@H](C(=O)N[C@H]1CC[C@H](N(CC1=O)S(=O)(=O)c1ccccn1)C)NC(=O)c1cc2c(o1)cccc2)C
InChI InChI=1S/C27H32N4O6S/c1-17(2)14-21(30-27(34)24-15-19-8-4-5-9-23(19)37-24)26(33)29-20-12-11-18(3)31(16-22(20)32)38(35,36)25-10-6-7-13-28-25/h4-10,13,15,17-18,20-21H,11-12,14,16H2,1-3H3,(H,29,33)(H,30,34)/t18-,20+,21+/m1/s1
InChI Key BWYBBMQLUKXECQ-GIVPXCGWSA-N
Bioactivity Comments
Relacatib has activity against cathepsin L in addition to cathepsin K [2]. Inhibition of endosomal cathepsins B and L can partially block SARS-Cov-2 entry into host cells in vitro, so relacatib could be tested for this action.
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
cathepsin K Primary target of this compound Hs Inhibitor Inhibition 9.4 pKi - 1
pKi 9.4 (Ki 4.1x10-10 M) [1]